Jos De Man

Oss, NB, Netherlands

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 17 publications

Dual TTK/PLK1 inhibition has potent anticancer activity in TNBC as monotherapy and in combination.

Dual TTK/PLK1 inhibition has potent anticancer activity in TNBC as monotherapy and in combination.

Journal: Frontiers in oncology

Published: June 12, 2024

LCK inhibition downregulates YAP activity and is therapeutic in patient-derived models of cholangiocarcinoma.

LCK inhibition downregulates YAP activity and is therapeutic in patient-derived models of cholangiocarcinoma.

Journal: Journal of hepatology

Published: October 06, 2021

Targeting Indoleamine 2,3-Dioxygenase in Cancer Models Using the Novel Small Molecule Inhibitor NTRC 3883-0.

Targeting Indoleamine 2,3-Dioxygenase in Cancer Models Using the Novel Small Molecule Inhibitor NTRC 3883-0.

Journal: Frontiers in immunology

Published: September 23, 2020

Pharmacological validation of TDO as a target for Parkinson's disease.

Pharmacological validation of TDO as a target for Parkinson's disease.

Journal: The FEBS journal

Published: September 11, 2020

High-Throughput Fluorescence-Based Activity Assay for Arginase-1.

High-Throughput Fluorescence-Based Activity Assay for Arginase-1.

Journal: SLAS discovery : advancing life sciences R & D

Published: May 19, 2020

Structural insights into human Arginase-1 pH dependence and its inhibition by the small molecule inhibitor CB-1158.

Structural insights into human Arginase-1 pH dependence and its inhibition by the small molecule inhibitor CB-1158.

Journal: Journal of structural biology: X

Published: October 19, 2019

Combined Cellular and Biochemical Profiling to Identify Predictive Drug Response Biomarkers for Kinase Inhibitors Approved for Clinical Use between 2013 and 2017.

Combined Cellular and Biochemical Profiling to Identify Predictive Drug Response Biomarkers for Kinase Inhibitors Approved for Clinical Use between 2013 and 2017.

Journal: Molecular cancer therapeutics

Published: August 03, 2018

TTK Inhibitors as a Targeted Therapy for CTNNB1 (β-catenin) Mutant Cancers.

TTK Inhibitors as a Targeted Therapy for CTNNB1 (β-catenin) Mutant Cancers.

Journal: Molecular cancer therapeutics

Published: April 19, 2017

Target Residence Time-Guided Optimization on TTK Kinase Results in Inhibitors with Potent Anti-Proliferative Activity.

Target Residence Time-Guided Optimization on TTK Kinase Results in Inhibitors with Potent Anti-Proliferative Activity.

Journal: Journal of molecular biology

Published: March 25, 2017

Stable aneuploid tumors cells are more sensitive to TTK inhibition than chromosomally unstable cell lines.

Stable aneuploid tumors cells are more sensitive to TTK inhibition than chromosomally unstable cell lines.

Journal: Oncotarget

Published: November 16, 2016

Compound Selectivity and Target Residence Time of Kinase Inhibitors Studied with Surface Plasmon Resonance.

Compound Selectivity and Target Residence Time of Kinase Inhibitors Studied with Surface Plasmon Resonance.

Journal: Journal of molecular biology

Published: October 31, 2016

Cell Panel Profiling Reveals Conserved Therapeutic Clusters and Differentiates the Mechanism of Action of Different PI3K/mTOR, Aurora Kinase and EZH2 Inhibitors.

Cell Panel Profiling Reveals Conserved Therapeutic Clusters and Differentiates the Mechanism of Action of Different PI3K/mTOR, Aurora Kinase and EZH2 Inhibitors.

Journal: Molecular cancer therapeutics

Published: June 22, 2016

Showing 1-12 of 17

Last Updated: 09/26/2026